Based on the evidence mentioned above, we hypothesized that inhibition of PDE5 might be associated with a reduced risk of tumor progression and mortality among patients with CRC, and the effect might be stronger among patients who have received open surgery. This evidence concerns the gene PDE5A and colorectal carcinoma.